Immatics (IMTX) Revenue & Revenue Breakdown


OverviewForecastOwnershipFinancialsChart

Immatics Revenue Highlights


Latest Revenue (Y)

$54.00M

Latest Revenue (Q)

$30.45M

Immatics Revenue by Period


Immatics Revenue by Year

DateRevenueChange
2023-12-31$54.00M-68.76%
2022-12-31$172.83M397.17%
2021-12-31$34.76M11.23%
2020-12-31$31.25M69.40%
2019-12-31$18.45M389.36%
2018-12-31$3.77M-

Immatics generated $54.00M in revenue during NA 2023, up -68.76% compared to the previous quarter, and up 1432.28% compared to the same period a year ago.

Immatics Revenue by Quarter

DateRevenueChange
2024-03-31$30.45M91.24%
2023-12-31$15.92M168.66%
2023-09-30$5.93M-73.49%
2023-06-30$22.35M128.20%
2023-03-31$9.80M-73.98%
2022-12-31$37.65M149.99%
2022-09-30$15.06M-12.52%
2022-06-30$17.21M-83.27%
2022-03-31$102.91M554.33%
2021-12-31$15.73M144.09%
2021-09-30$6.44M24.17%
2021-06-30$5.19M-29.91%
2021-03-31$7.40M-21.63%
2020-12-31$9.45M20.01%
2020-09-30$7.87M14.14%
2020-06-30$6.90M-2.05%
2020-03-31$7.04M60.58%
2019-12-31$4.38M-13.29%
2019-09-30$5.06M-6.09%
2019-06-30$5.38M16.73%
2019-03-31$4.61M389.36%
2018-12-31$942.50K-
2018-09-30$942.50K-
2018-06-30$942.50K-
2018-03-31$942.50K-

Immatics generated $30.45M in revenue during Q1 2024, up 91.24% compared to the previous quarter, and up 80.87% compared to the same period a year ago.

Immatics Peer Comparison by Revenue


TickerCompanyLast Year RevenueLast Quarter Revenue
HRMYHarmony Biosciences$582.02M$186.04M
IMTXImmatics$54.00M$30.45M
MRUSMerus$43.95M$11.77M
FENCFennec Pharmaceuticals$21.64M$25.26M
JANXJanux Therapeutics$8.08M$1.25M
KRONKronos Bio$6.29M$2.69M
CRNXCrinetics Pharmaceuticals$4.01M$640.00K
INBXInhibrx Biosciences$1.80M-
KROSKeros Therapeutics$151.00K$83.00K
LYELLyell Immunopharma$130.00K$3.00K
ALXOALX Oncology--
BCABBioAtla--
AVTEAerovate Therapeutics--
REPLReplimune Group--
SNDXSyndax Pharmaceuticals-$3.50M
MLYSMineralys Therapeutics--
EWTXEdgewise Therapeutics--

IMTX Revenue FAQ


Immatics's yearly revenue for 2023 was $54M, representing a decrease of -68.76% compared to 2022. The company's yearly revenue for 2022 was $172.83M, representing an increase of 397.17% compared to 2021. IMTX's yearly revenue for 2021 was $34.76M, representing an increase of 11.23% compared to 2020.

Immatics's quarterly revenue for Q1 2024 was $30.45M, a 91.24% increase from the previous quarter (Q4 2023), and a 210.81% increase year-over-year (Q1 2023). The company's quarterly revenue for Q4 2023 was $15.92M, a 168.66% increase from the previous quarter (Q3 2023), and a -57.71% decrease year-over-year (Q4 2022). IMTX's quarterly revenue for Q3 2023 was $5.93M, a -73.49% decrease from the previous quarter (Q2 2023), and a -60.65% decrease year-over-year (Q3 2022).

Immatics's revenue growth rate for the last 3 years (2021-2023) was 55.33%, and for the last 5 years (2019-2023) was 192.68%.